Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

213 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combination of Deauville score and quantitative positron emission tomography parameters as a predictive tool of anti-CD19 chimeric antigen receptor T-cell efficacy.
Guidetti A, Dodero A, Lorenzoni A, Pizzamiglio S, Argiroffi G, Chiappella A, Bagnoli F, Marasco V, Carniti C, Monfrini C, Seregni E, Pennisi M, Verderio P, Alessi A, Corradini P. Guidetti A, et al. Among authors: seregni e. Cancer. 2023 Jan 15;129(2):255-263. doi: 10.1002/cncr.34532. Epub 2022 Nov 17. Cancer. 2023. PMID: 36385707 Free PMC article.
Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy: possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results.
Chiesa C, Botta F, Di Betta E, Coliva A, Maccauro M, Aliberti G, Bavusi S, Devizzi L, Guidetti A, Seregni E, Gianni AM, Bombardieri E. Chiesa C, et al. Among authors: seregni e. Cancer Biother Radiopharm. 2007 Feb;22(1):113-20. doi: 10.1089/cbr.2007.302. Cancer Biother Radiopharm. 2007. PMID: 17627419 Clinical Trial.
High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation.
Devizzi L, Guidetti A, Tarella C, Magni M, Matteucci P, Seregni E, Chiesa C, Bombardieri E, Di Nicola M, Carlo-Stella C, Gianni AM. Devizzi L, et al. Among authors: seregni e. J Clin Oncol. 2008 Nov 10;26(32):5175-82. doi: 10.1200/JCO.2008.16.8294. Epub 2008 Oct 14. J Clin Oncol. 2008. PMID: 18854569 Clinical Trial.
Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin).
Chiesa C, Botta F, Coliva A, Maccauro M, Devizzi L, Guidetti A, Carlo-Stella C, Seregni E, Gianni MA, Bombardieri E. Chiesa C, et al. Among authors: seregni e. Eur J Nucl Med Mol Imaging. 2009 Nov;36(11):1745-57. doi: 10.1007/s00259-009-1141-x. Epub 2009 May 20. Eur J Nucl Med Mol Imaging. 2009. PMID: 19455328 Clinical Trial.
Post-Synthesis Incorporation of ⁶⁴Cu in CuS Nanocrystals to Radiolabel Photothermal Probes: A Feasible Approach for Clinics.
Riedinger A, Avellini T, Curcio A, Asti M, Xie Y, Tu R, Marras S, Lorenzoni A, Rubagotti S, Iori M, Capponi PC, Versari A, Manna L, Seregni E, Pellegrino T. Riedinger A, et al. Among authors: seregni e. J Am Chem Soc. 2015 Dec 9;137(48):15145-51. doi: 10.1021/jacs.5b07973. Epub 2015 Nov 25. J Am Chem Soc. 2015. PMID: 26551614 Free article.
213 results